CADILA HEALTHCARE LTD. - 532321 - Updates
Update COVID-1907-05-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets02-05-2020
CADILA HEALTHCARE LTD. - 532321 - Certificate Under Regulation 40(10) Of SEBI Listing Regulations, 2015
Certificate under Regulation 40(10) of SEBI Listing Regulations, 201501-05-2020
In race to stop Covid-19, Indian drugmakers to conduct clinical trials
Glenmark, Zydus Cadila to start trials in May30-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Divestment of 49% shares of Windlas Healthcare Private Limited.30-04-2020
CADILA HEALTHCARE LTD. - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DIP) Regulations, 201828-04-2020
Cadila Healthcare Surges As Zydus Explores Drug To Treat COVID-19
Zydus Cadila said that its biological therapy Pegylated Interferon alpha-2b, 'PegiHepTM' can emerge as one of the pathways to treat COVID 19.21-04-2020
CADILA HEALTHCARE LTD. - 532321 - Shareholding for the Period Ended March 31, 2020
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here20-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b20-04-2020
Zydus Cadila gets USFDA nod to market muscle spasms tablets
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Baclofen tablets in the strength of 5 mg, Zydus Cadila said in a statement.18-04-2020